Scholarlink

Background <p>The aim of this study was to investigate the preclinical biodistribution and molecular pathway of [<sup>68</sup>Ga]Ga-BP-IDA and to evaluate its clinical suitability for quantitative monitoring of liver function during transarterial radioembolization (TARE) therapy of a hepatocellular carcinoma (HCC).</p> Results <p>[<sup>68</sup>Ga]Ga-BP-IDA undergoes hepatobiliary clearance, with uptake into hepatocytes via OATP1B1 and OATP1B3. [<sup>68</sup>Ga]Ga-BP-IDA exhibits demetallation in vivo but is nevertheless suitable for clinical application due to its rapid uptake into functional liver tissue. In a clinical case [<sup>68</sup>Ga]Ga-BP-IDA PET/CT allowed for differentiation of functional liver mass from cancerous tissue and enabled monitoring the effect on liver and tumor volume as well as on residual liver function after TARE therapy. Following TARE treatment, a reduction of the hepatic uptake rate was observed in both non-cancerous liver lobes, but was more pronounced in the right lobe, indicating a correlation to the higher non-targeted radiation dose from the TARE treatment in this lobe. [<sup>68</sup>Ga]Ga-BP-IDA PET/CT thus revealed additional information on liver function impairment which was not represented by CT-based volumetry alone.</p> Conclusion <p>[<sup>68</sup>Ga]Ga-BP-IDA PET/CT is a suitable tool for planning and monitoring TARE therapy of primary liver tumors and may complement the limits of volumetry-based methods with functional information about the liver.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hepatobiliary PET with [68Ga]Ga-BP-IDA – preclinical evaluation and its translational potential for liver function monitoring

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月2日

查看全文
  • Julia Greiser,
  • Robert Drescher,
  • Marta Pomraenke,
  • Mitali Sonawane,
  • Olga Perkas,
  • Christian Kuehnel,
  • Thomas Scholz,
  • Sebastian Groeber,
  • Thomas Weisheit,
  • Adrian Press,
  • Thomas Winkens,
  • Nathalie Viohl,
  • Anke Werner,
  • Michael Bauer,
  • Martin Freesmeyer

摘要

Background

The aim of this study was to investigate the preclinical biodistribution and molecular pathway of [68Ga]Ga-BP-IDA and to evaluate its clinical suitability for quantitative monitoring of liver function during transarterial radioembolization (TARE) therapy of a hepatocellular carcinoma (HCC).

Results

[68Ga]Ga-BP-IDA undergoes hepatobiliary clearance, with uptake into hepatocytes via OATP1B1 and OATP1B3. [68Ga]Ga-BP-IDA exhibits demetallation in vivo but is nevertheless suitable for clinical application due to its rapid uptake into functional liver tissue. In a clinical case [68Ga]Ga-BP-IDA PET/CT allowed for differentiation of functional liver mass from cancerous tissue and enabled monitoring the effect on liver and tumor volume as well as on residual liver function after TARE therapy. Following TARE treatment, a reduction of the hepatic uptake rate was observed in both non-cancerous liver lobes, but was more pronounced in the right lobe, indicating a correlation to the higher non-targeted radiation dose from the TARE treatment in this lobe. [68Ga]Ga-BP-IDA PET/CT thus revealed additional information on liver function impairment which was not represented by CT-based volumetry alone.

Conclusion

[68Ga]Ga-BP-IDA PET/CT is a suitable tool for planning and monitoring TARE therapy of primary liver tumors and may complement the limits of volumetry-based methods with functional information about the liver.